Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2003
11/18/2003CA2127472C New adenosine derivatives, preparation methods and pharmaceutical compositions containing them
11/18/2003CA2072233C Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them
11/14/2003CA2428514A1 Resistant starch prepared by isoamylase debranching of low amylose starch
11/13/2003WO2003093456A1 Soya cell strains with high isoflavone content
11/13/2003WO2003093422A2 Novel tissue factor targeted antibodies as anticoagulants
11/13/2003WO2003093409A2 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003WO2003093317A1 Antibody to human insulin-like growth factor
11/13/2003WO2003093297A2 Protein kinase modulators and methods of use
11/13/2003WO2003093276A1 A process for the preparation of clopidogrel
11/13/2003WO2003093267A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
11/13/2003WO2003093263A1 Substituted imidazole derivatives: gabaa receptor ligands
11/13/2003WO2003093254A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003WO2003093249A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003WO2003093248A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
11/13/2003WO2003093242A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
11/13/2003WO2003093240A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003WO2003093237A1 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
11/13/2003WO2003093235A1 Carboxylic acid amides
11/13/2003WO2003093234A1 Melanocortin receptor ligands
11/13/2003WO2003092767A2 A method for inhibiting platelet aggregation
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092731A1 Stabilised solid compositions of modified factor vii
11/13/2003WO2003092721A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes
11/13/2003WO2003092720A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
11/13/2003WO2003092715A2 Proteins involved in the regulation of energy homeostasis
11/13/2003WO2003092709A1 Method for producing preparations rich in tocotrienol
11/13/2003WO2003092699A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003WO2003092693A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003WO2003092690A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003WO2003092686A1 Inhibitors of histone deacetylase
11/13/2003WO2003092678A1 1-substituted imidazole derivatives as nos inhibitors
11/13/2003WO2003092673A1 Use of epa and dha in secondary prevention
11/13/2003WO2003092670A1 Bombesin antagonists
11/13/2003WO2003092669A2 Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
11/13/2003WO2003092660A1 Monocompartment osmotic controlled drug delivery system
11/13/2003WO2003092657A1 Microparticles bearing cells and active substances
11/13/2003WO2003092626A2 Carvedilol pharmasolve solvate
11/13/2003WO2003092625A2 Carvedilol formulations
11/13/2003WO2003092624A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003WO2003092613A2 Catechin multimers as therapeutic drug delivery agents
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092602A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003WO2003092599A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003WO2003092588A2 4-azasteroid derivatives as androgen receptor modulators
11/13/2003WO2003092585A2 Controlled release compositions of estradiol metabolites
11/13/2003WO2003092580A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003WO2003076417A3 Oxo-azabicyclic compounds
11/13/2003WO2003066621A8 Piperidine derivatives and their use as antagonists of tachykinins
11/13/2003WO2003064447A3 Immune-modulating peptide
11/13/2003WO2003061365A3 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/13/2003WO2003057688A3 Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
11/13/2003WO2003042113A8 Production of cell suspensions
11/13/2003WO2003041563A3 Neurotransmitter balance chemotherapy
11/13/2003WO2003040691A3 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
11/13/2003WO2003035008A3 Functionalized stilbene derivatives as improved vascular targeting agents
11/13/2003WO2003033653A3 Affinity enhancement agents
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003031407A3 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029200A3 Compounds useful as reversible inhibitors of cysteine proteases
11/13/2003WO2003028727A9 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors
11/13/2003WO2003028536A3 Methods for diagnosing and treating heart disease
11/13/2003WO2003022360A3 Thermotherapy via targeted delivery of nanoscale magnetic particles
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2003017939A3 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2003008005A3 Catheter and implants for the delivery of therapeutic agents to tissues
11/13/2003WO2003002755A3 Glaucoma treatments with reduced hyperpigmentation
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002092831A3 Method for identifying ligands for g protein coupled receptors
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002072888A3 Polymorphisms in the human cmoat gene and uses thereof
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002057226A8 68730 and 69112 protein kinase molecules and uses therefor
11/13/2003WO2002056893A8 Novel receptors for $i(helicobacter pylori) and use thereof
11/13/2003WO2002048715A3 Inflammatory markers for detection and prevention of diabetes mellitus
11/13/2003US20030212277 Using 3-sulfonylchloride-4-chloro)pyridine as chemical intermediate
11/13/2003US20030212272 Vasodilation; hypotensive agents; cardiovascular disorders
11/13/2003US20030212269 Kinase inhibitor; antitumor agents, psoriasis, skin disorders, antiarthritic agents
11/13/2003US20030212266 Growth arrest homeobox gene
11/13/2003US20030212145 Parkinson's disease; cognition activators; central nervous system disorders
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212137 Administering a thyroid hormone receptor beta agonist and fibrate to lower triglyceride levels in blood
11/13/2003US20030212114 Stable emulsion compositions
11/13/2003US20030212100 Antidiabetic agnets; insulin resistance
11/13/2003US20030212097 Osteoporosis, antiarthrtic agents; antitumor agents
11/13/2003US20030212096 Analgesics, antiinflammatory agents, autoimmune disease, viricides, bactericides, antitumor agents, organ grafting, central nervous system disorders
11/13/2003US20030212094 Novel cyclic amide derivatives
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212071 Controlling blood coagulation
11/13/2003US20030212070 Dietetics; cardiovascular disorders; hypotensive agents; psychological disorders
11/13/2003US20030212069 Antithrombotic amides
1 ... 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 ... 1595